Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

• Sonnet Biotherapeutics Holdings Inc SONN.OQ reported a quarterly adjusted loss of 95 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-5.60. The lone analyst forecast for the quarter was for a loss of 49 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Sonnet Biotherapeutics Holdings Inc's reported EPS for the quarter was a loss of 95 cents​.

• Sonnet Biotherapeutics Holdings Inc shares had risen by 218.5% this quarter and gained 170.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Sonnet Biotherapeutics Holdings Inc is $20.00, about 80.3% above its last closing price of $3.95

This summary was machine generated from LSEG data August 14 at 03:37 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)